Skip to main
EQ

Equillium Inc (EQ) Stock Forecast & Price Target

Equillium Inc (EQ) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Equillium Inc. is positioned positively due to the promising efficacy of its lead candidate, EQ504, showing notable immunomodulatory effects in patients with ulcerative colitis, including multiple patients achieving clinical remission. The observed improvement in liver function tests and significant reductions in endoscopic scores support the potential for EQ504 to succeed in clinical applications, further enhancing confidence in its development. With the projected timeline for Phase 1 initiation set for mid-2026, the robust early data suggests substantial value creation opportunities for the company as it advances its therapeutic pipeline.

Bears say

Equillium Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily due to the uncertain clinical trajectory of its lead product, EQ504. Potential competitive threats from developments like Azora’s AT-177 and concerns about safety signals or negative Phase 1 data could diminish EQ504's market positioning and overall value, potentially leading to substantial declines in stock price. Furthermore, failure to secure favorable financing for Phase 2a trials or adverse developments related to the AhR therapeutic index could result in dilutive financing at unfavorable terms, exacerbating financial vulnerabilities.

Equillium Inc (EQ) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Equillium Inc (EQ) Forecast

Analysts have given Equillium Inc (EQ) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Equillium Inc (EQ) has a Strong Buy consensus rating as of Apr 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Equillium Inc (EQ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.